Latest News

etf-securities-white-only.png
GOLD a performer for troubled times • Mounting uncertainty in 2019 calls for portfolio diversification and a keen focus on reducing losses • A standout monthly rise by ETFS Physical Gold (ASX code: GOLD) - up more than 9%, and 11% for Q4, far exceeding the broader share market ETF Securities today urged investors to consider the benefits of gold as 2019 shapes up to be a year of uncertainty. “Investment markets displayed heightened volatility going into the close of 2018,” said ETF Securities Chief Executive, Kris Walesby. “We don’t expect the landscape to change, which should put gold front and centre as a safe refuge this year.” ...
etf-securities-white-only.png
ETF Securities expands talent pool amid market growth SYDNEY, November 19 – ETF Securities today said it is continuing to expand its workforce and develop its product range in a market that is being strongly embraced by Australian investors. “We are a growing business in a dynamic sector of the market. ETFs are the fastest growing product type in Australia, with funds under management posting annual growth of nearly 22 percent to more than $40 billion at the end of October,” said ETF Securities Australia Chief Executive Kris Walesby. “Developing our talent pool is an important part of staying at the cutting edge of the industry,” Mr Walesby said. British Olympian Larry Achike joins ETF Securities in the Business Development team after heading sales and business development at Surgicore Australia. ...
etf-securities-white-only.png
Just what the doctor ordered - CURE biotech ETF now available (ASX code: CURE) • CURE is Australia’s only pure-play biotech ETF • Provides access to a range of companies including the world’s leading producer of orphan drugs and another with more than US$5 billion in sales for its rheumatoid arthritis treatment • CURE is the latest in the ‘Future Present’ ETF range designed to deliver outsized returns SYDNEY, November 12 – ETF Securities has launched its CURE exchange traded fund (ETF) on the ASX, providing Australian investors with broad-based exposure to some of the world’s most exciting healthcare biotechnology companies. ...